Investors were initially encouraged when early indications pointed to a positive response among Alzheimer’s patients among patients receiving an anti-amyloid beta protofibril antibody from US biotech Biogen (Nasdaq: BIIB) and Japanese pharma major Eisai (TYO: 4523).
The drug, BAN2401, had shown a reduction in amyloid plaques, the protein that, according to many hypotheses, is behind the development of Alzheimer’s.
But when the companies presented more detailed data on the Phase II Study 201 trial late on Wednesday, the companies’ share started to go the other way.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze